SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
WARREN, N.J., April 03, 2018 -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will provide a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference, taking place April 8-10, 2018, in Monte Carlo, Monaco.
Bellerophon Presentation Details
Date: Tuesday, April 10, 2018
Time: 10:15 AM Central European Summer Time/4:15 AM Eastern Time
Location: Monte Carlo, Monaco - Le Meridien Beach Plaza Hotel
The presentation will be webcast live and archived for 90 days on Bellerophon's Investor Relations website at investors.bellerophon.com.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of PAH, for which the Company has commenced Phase 3 clinical trials. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD), both of which are in Phase 2 development. For more information, please visit www.bellerophon.com.
Contact
Bellerophon Therapeutics:
Fabian Tenenbaum, Chief Executive Officer
(908) 574-4767
LifeSci Advisors
Brian Ritchie
212-915-2578
[email protected]
